Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2016 recommendations of the international antiviral society-usa panel. JAMA 2016; 316(2): 191-210.
Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012; 2(4): a007161.
Beyrer C, Pozniak A. HIV Drug Resistance - an emerging threat to epidemic control. N Engl J Med 2017; 377(17): 1605-7.
Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37(1): 113-28.
Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol 2016; 46: 292-307.
Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347(6): 385-94.
Panichsillapakit T, Smith DM, Wertheim JO, Richman DD, Little SJ, Mehta SR. Prevalence of transmitted HIV drug resistance among recently infected persons in san diego, CA 1996-2013. J Acquir Immune Defic Syndr 2016; 71(2): 228-36.
Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(Suppl. 2): 25-36.
Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med 2015; 12(4): e1001810.
Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74(12): 5463-7.
Shafer RW. Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J Infect Dis 2009; 199(5): 610-2.
Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012; 72(9): e1-e25.
Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199(5): 693-701.
Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5(7): e158.
Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. Journal of acquired immune deficiency syndromes 2005; 38(1): 37-42.
Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res 2010; 85(1): 245-65.
Wensing AM, Calvez V, Gunthard HF, et al. 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med 2017; 24(4): 132-3.
Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4(3): e4724.
Dudley DM, Chin EN, Bimber BN, et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012; 7(5): e36494.
Tang MW, Liu TF, Shafer RW. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology 2012; 55(2): 98-101.
Nicot F, Saliou A, Raymond S, et al. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J Clin Virol 2012; 55(2): 107-13.
Hofstra LM, Sauvageot N, Albert J, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in europe. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2016; 62(5): 655-63.
Boyd MA, Moore CL, Molina JM, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV 2015; 2(2): e42-51.
Sayan M, Willke A, Ozgunes N, Sargin F. HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey. Jpn J Infect Dis 2013; 66(4): 306-11.
Sayan M, Sargin F, Inan D, et al. HIV-1 Transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in turkey. AIDS Res Hum Retroviruses 2016; 32(1): 26-31.
Korten V, Inan D, Yildirmak T, et al. Prevalence of transmitted drug resistance (TDR) in newly diagnosed HIV-1 infected patients in Turkey. 14th European AIDS Conference (EACS). Brussels, Belgium. 2013.
Kuskucu MA, Midilli K, Yemisen M, Abdelkareem A, Ergin S, Tabak F. Transmitted drug resistance (TDR) prevalance among treatment naive HIV-1 infected patients in Istanbul remained unchanged between 2004 and 2015. 18th Annual Meeting of European Society for Clinical Virology. Edinburgh, UK. 2015.
Yalcinkaya T, Kose S. Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases. Mikrobiyol Bul 2014; 48(4): 585-95.
Avila-Rios S, Garcia-Morales C, Matias-Florentino M, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Lancet HIV 2016; 3(12): e579-91.
Iwuji C, Derache A, Baisley K, et al. Response to first-line ART in adults with drug resistant HIV, ANRS 12249 TasP trial. Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. 2017.
Ji H, Liang B, Li Y, et al. Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing. J Virol Methods 2013; 187(2): 314-20.
Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9: 387-402.
Shafer RW. Human immunodeficiency virus type 1 drug resistance mutations update. J Infect Dis 2017; 216(Suppl. 9): S843-6.